awmsg logo



pomalidomide (Imnovid®)


Reference No. 3515

Publication date:
18/09/2019


Appraisal information

pomalidomide (Imnovid®) 1 mg capsule
pomalidomide (Imnovid®) 2 mg capsule
pomalidomide (Imnovid®) 3 mg capsule
pomalidomide (Imnovid®) 4 mg capsule


Company: Celgene Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
   
   
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 16/09/2019

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, pomalidomide (Imnovid®) cannot be endorsed for use within NHS Wales in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.
Statement of Advice (SOA)
Download